Morepen Labs Executes Rs 50 Crore Term Loan Agreement with Woori Bank
Morepen Laboratories Limited executed a loan agreement with Woori Bank for an unsecured term loan of ₹50 crore. The loan has a 3-year tenure with 8 quarterly repayments after a one-year moratorium. The interest rate is 7.40% p.a. Mr. Sushil Suri provided a personal guarantee. Outstanding loans were ₹137.70 crore.
The infusion of ₹50 crore can support the company's general corporate purposes and potentially improve its working capital. However, the impact is considered medium as it's a standard debt financing activity and not a transformative event.
The company has secured a term loan, which is a standard financing activity. While it provides capital, the terms and the need for a personal guarantee do not indicate a strongly positive or negative development on their own.
Morepen Laboratories Limited has executed a loan agreement and other related documents with Woori Bank for an unsecured term loan facility amounting to ₹50 crore.
The agreement, executed on February 12, 2026, is for general corporate purposes. The loan carries an interest rate of the prevailing repo rate plus 1.32% per annum, with a current effective rate of 7.40% per annum. The tenure of the loan is 3 years, with repayment structured as 8 equal quarterly principal repayments after a one-year moratorium period from the drawdown date.
This unsecured term loan facility is supported by a personal guarantee from Mr. Sushil Suri, Promoter, Chairman & Managing Director of the company. As of February 12, 2026, the company's outstanding loans, excluding interest and vehicle loans, stood at ₹137.70 crore.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.